跳转至内容
Merck

G2536

Sigma-Aldrich

更昔洛韦

≥99% (HPLC), powder, viral DNA elongation inhibitor

别名:

2-氨基-1,9-二氢-9-[[2-羟基-1-(羟甲基)乙氧基]甲基]-6H-嘌呤-6-酮, 9-(1,3-二羟基-2-丙氧甲基)鸟嘌呤, DHPG

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C9H13N5O4
CAS号:
分子量:
255.23
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

更昔洛韦, ≥99% (HPLC), powder

品質等級

化驗

≥99% (HPLC)

形狀

powder

顏色

white

溶解度

0.1 M HCl: 10 mg/mL

&epsilon ;(消光係數)

12.0 at 256 nm at 1 mM

抗生素活性譜

viruses

作用方式

DNA synthesis | interferes

起源

Roche

儲存溫度

2-8°C

SMILES 字串

NC1=Nc2c(ncn2COC(CO)CO)C(=O)N1

InChI

1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)

InChI 密鑰

IRSCQMHQWWYFCW-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

化学结构:核苷

應用

分子生物学中,当需要对目的基因进行同源重组时,更昔洛韦可用于选择随机重组事件。

生化/生理作用

更昔洛韦是一种前药核苷类似物,通过磷酸化激活。可用于癌症研究中基因治疗的研究。
在编码胸苷激酶的病毒自杀基因表达后,无毒前药转化成磷酸化的活性类似物并掺入复制真核细胞的DNA中,导致恶性分裂细胞死亡。在G2-M检查点不可逆转地阻滞细胞周期。研究了间隙连接在更昔洛韦旁观者效应中的参与情况。更昔洛韦用于研究端粒丢失 和评估病毒对抗病毒治疗的敏感性。

特點和優勢

该化合物是ADME Tox研究的特色产品。点击此处 了解更多ADME Tox的特色产品。了解更多有关用于其他研究领域的生物活性小分子的信息,请访问sigma.com/discover-bsm
该化合物由 Roche开发。想浏览其他制药公司开发的化合物和已批准药物/候选药物目录, 请单击此处

準備報告

更昔洛韦可溶于0.1 M HCl(10 mg/ml)、DMSO(5 mg/ml)、水(2 mg/ml)、热甲醇和乙醇(<1 mg/ml)。
本品应在2-8℃下干燥保存,在此条件下可稳定保存3年。

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Muta. 1B - Repr. 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Zhanguo Gao et al.
Biomolecules, 11(10) (2021-10-24)
Duchenne muscular dystrophy (DMD), caused by the loss of dystrophin, remains incurable. Reduction in muscle regeneration with DMD is associated with the accumulation of fibroadipogenic progenitors (FAPs) differentiating into myofibroblasts and leading to a buildup of the collagenous tissue aggravating
Sunwen Chou
Reviews in medical virology, 18(4), 233-246 (2008-04-03)
Mutations in the human CMV UL97 kinase gene are a major mechanism of viral resistance to two anti-CMV drugs, ganciclovir (GCV) and maribavir (MBV). GCV, the most widely used and established therapy for CMV, is a substrate for the UL97
Julie Cates Scott et al.
Therapeutic drug monitoring, 26(1), 68-77 (2004-01-30)
The authors use a previously published decision-making algorithm to address the role of clinical pharmacokinetic monitoring of ganciclovir, the drug of choice for prophylaxis and treatment of cytomegalovirus (CMV) in solid organ transplant recipients. Ganciclovir pharmacokinetics have been studied in
Koenraad Smets et al.
European journal of pediatrics, 165(12), 885-890 (2006-06-21)
The objective of this study is to look for evidence based or scientific guidelines for selection of newborns with congenital cytomegalovirus (CMV) infection that might benefit from treatment with ganciclovir. A literature search was conducted involving the MEDLINE database and
L Z Rubsam et al.
Cancer research, 59(3), 669-675 (1999-02-11)
The ability of herpes simplex virus type 1 thymidine kinase (HSV-TK)-expressing cells incubated with ganciclovir (GCV) to induce cytotoxicity in neighboring HSV-TK-negative (bystander) cells has been well documented. Although it has been suggested that this bystander cell killing occurs through

商品

DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.

DNA损伤和修复机制对于维持DNA完整性至关重要。细胞DNA的损伤与突变、癌症发展等有关。

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Discover Bioactive Small Molecules for ADME/Tox

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门